slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 44,671-44,700
Pages 10,126
Rows per page 30
Component
44,671-44,700 of 303,780
26
argenx SE | Investor Conference Presentation Deck | 27 slidesargenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement2 hits
04
The slide uses a horizontal layout to segment the business into five pillars, each with specific growth drivers and outlooks.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Early StrugglesLoop · Logic Chain2 hits
05
The right-hand side is a complex matrix mapping clinical trials to patient segments (HER2-positive, HR-positive, TNBC, gBRCAm) and treatment stages (Neoadjuvant, Adjuvant, Metastatic).AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Early StrugglesLoop · Logic Chain2 hits
06
The slide uses a structured grid to map corporate acquisitions/partnerships to strategic goals and therapeutic areas.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Early StrugglesLoop · Logic Chain2 hits
08
The slide uses a structured layout to present the company's oncology portfolio, categorizing drugs by their therapeutic focus and market position.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising SuccessLoop · Logic Chain2 hits
09
Includes specific drug names and market projections for 2028.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising SuccessLoop · Logic Chain2 hits
11
The slide uses a three-column layout to categorize business units and their respective growth drivers.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success2 hits
12
NME stands for New Molecular Entity. FDC stands for Fixed-Dose Combination.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success2 hits
13
Includes clinical development pipeline visualization and market growth projections.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success2 hits
14
Includes a table comparing hospitalization rates for RSV, hMPV, and Influenza across age groups.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success2 hits
16
The slide uses a waterfall-style growth diagram for Ultomiris and a combination of bar charts and bulleted metrics for HPP assets.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction2 hits
17
The slide uses a split layout: left side details specific drug assets (anselamimab, ALXN2220) with clinical stage data, right side outlines the genomic medicine strategy.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction2 hits
19
The slide highlights both internal R&D focus areas and external acquisitions (Cellectis, Quell, Gracell) to support long-term growth.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement2 hits
20
Includes specific targets for 2025, 2026, and 2030.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement2 hits
21
The slide uses a four-column layout to highlight key strategic pillars.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement2 hits
05
The slide uses a table-like structure to track progress (checkmarks for completed, squares for upcoming) across 8 distinct drug programs.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
07
Includes two line charts showing PK and PD profiles across different dosage levels.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
08
The slide outlines a 12-week open-label study with a specific focus on treatment-resistant depression (TRD).ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
11
Includes a map of global disease burden and key product features.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
13
The slide uses a process flow diagram to show the progression of the trial parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
15
The slide uses a line chart to show the change in MADRS scores over 12 weeks for three different dosages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
18
The chart illustrates the pharmacokinetic advantage of IV delivery over oral administration.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
19
Includes trial objectives and timeline markers for both parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
21
Includes a map of the world as a visual anchor for global disease burden.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
26
ATAI | Investor Presentation Deck | 34 slidesATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
27
The slide demonstrates an inverted U-shaped dose response curve.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
28
The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
32
Slide 32 of the deck.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
33
The slide uses EEG power spectral density analysis to demonstrate target engagement and potential for a superior safety profile (less sedation) compared to standard benzodiazepines.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
04
The slide uses a value-chain style flow from left to right, emphasizing the integration of diverse data types into a central knowledge graph.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits